The Rosen Law Firm is encouraging investors in gene therapy company uniQure N.V. (NASDAQ: QURE) to seek legal representation before the April 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit targets shareholders who acquired company shares during the period between September 24, 2025 and October 31, 2025.
According to the litigation, uniQure allegedly made material misrepresentations and omissions regarding its Pivotal Study for a Huntington's Disease therapeutic candidate. Specifically, the complaint contends that the company failed to disclose that the clinical trial design had not received complete FDA approval. Additionally, the lawsuit claims uniQure downplayed the potential for delays to its Biologics License Application timeline, which would be necessary for regulatory approval and commercial launch of the candidate drug.
Investors who meet the specified purchase criteria are encouraged to consult with legal counsel to evaluate their eligibility to participate in the class action proceeding. The lead plaintiff designation process represents a critical juncture in securities litigation, as it determines the individual or entity that will represent the broader shareholder group throughout the case.